GlobeNewswire

Cogentix Medical, Inc. / Laborie Medical Technologies Canada ULC Merger Litigation

Share

TORONTO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- On March 11, 2018, Cogentix Medical, Inc. (“Cogentix”) and certain affiliates of Laborie Medical Technologies Canada ULC (“Laborie”), LM US Parent, Inc. (“Parent”) and Camden Merger Sub, Inc. (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) pursuant to which Cogentix would become a wholly-owned subsidiary of Parent (the “Merger”). Pursuant to the terms of the Merger Agreement, Merger Sub commenced a tender offer (the “Tender Offer”) to purchase all of the outstanding shares of Cogentix’s common stock. On March 26, 2018, in connection with the Tender Offer, Cogentix filed a Schedule 14D-9 Solicitation/Recommendation Statement with the United States Securities and Exchange Commission (the “SEC”).

Subsequent to the commencement of the Tender Offer and the filing of the Schedule 14D-9, Cogentix’s directors, Laborie, Parent, and Merger Sub were named as defendants in a purported class action lawsuit related to the proposed Merger that was filed in the Delaware Court of Chancery (Franchi v. Uri Geiger, et al., C.A. No. 2018-0258-AGB). The lawsuit generally alleged that Cogentix’s directors breached their fiduciary duties to Cogentix’s stockholders, and that Laborie, Parent, and Merger Sub aided and abetted the alleged breaches. The plaintiff also filed a motion to expedite proceedings and a preliminary injunction motion to enjoin the close of the Tender Offer and proposed Merger. After defendants produced certain confidential documents to plaintiff and Cogentix filed with the SEC an amendment to the Schedule 14D-9 on April 10, 2018 that contained additional disclosures relating to the Merger (the “Supplemental Disclosures”), plaintiff determined that the claims asserted in the complaint were mooted and plaintiff withdrew the pending expedition and injunction motions.

The Tender Offer expired on April 20, 2018, and the Merger was consummated on April 23, 2018, whereby Cogentix became a wholly-owned subsidiary of Parent and Cogentix’s common stock was delisted from the Nasdaq Capital Market. Subsequent to the closing of the Merger, plaintiff informed defendants that plaintiff had determined to dismiss the action with prejudice as to himself and without prejudice as to Cogentix’s other stockholders, and that plaintiff would seek an award of attorneys’ fees and expenses in connection with the Supplemental Disclosures. After plaintiff informed defendants of his determination to dismiss the action, the parties engaged in discussions regarding a potential resolution of plaintiff’s anticipated fee and expense application, and ultimately agreed to a payment made directly by Laborie to plaintiff’s counsel in the amount of $137,500.

The Delaware Court of Chancery subsequently entered an order that required the parties to provide notice of the dismissal of the action on mootness grounds and the agreed payment of plaintiff’s counsel’s fees and expenses to allow Cogentix and/or Laborie stockholders the opportunity to object. Pursuant to the Court’s order, following the expiration of a thirty-day notice period, the parties will inform the Court regarding any responses to the notice and, if appropriate, submit a proposed order providing that the action and the claims asserted therein are dismissed with prejudice as to the named plaintiff only, and without prejudice as to members of the putative class of Cogentix stockholders. With the exception of considering any potential objections to the payment of plaintiff’s counsel’s fees and expenses, the Court of Chancery has not been asked to review, and will pass no judgment on, the payment of a fee or its reasonableness.

Any objections to the dismissal of the action on mootness grounds and the proposed payment of plaintiff’s counsel’s fees and expenses should be sent within thirty days of the posting of this notice to counsel for plaintiff, Brian D. Long, at bdl@rl- legal.com or 300 Delaware Avenue, Suite 1220, Wilmington, DE 19801, and counsel for defendants, Steven L. Caponi, at steven.caponi@klgates.com or 600 N. King Street, Suite 901, Wilmington, DE 19801.

For Further Information:

LABORIE Medical Technologies
Joe Metzger
+1-978-273-5187

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Hoylu AB: Publicerar årsredovisning för 20192.6.2020 23:30:00 CESTPressemelding

Hoylu AB (publ) meddelar idag att årsredovisningen för räkenskapsåret 2019 finns tillgänglig på bolagets hemsida: https://www.hoylu.com/investor-relations/financial-reports/ För ytterligare information, vänligen kontakta: Stein Revelsby, VD på Hoylu + 1 213 440 2499 e-post: sr@hoylu.com Karl Wiersholm, CFO på Hoylu + 1 425 829 2316 e-post: kw@hoylu.com Om Hoylu Hoylus uppdrag är att göra distansarbete och informationsutbyte enkelt. Genom vår anpassningsbara Connected Workspaces™ levererar vi programvarulösningar till företag, organisationer och individer i praktiskt taget alla branscher som gör det möjligt för alla team, stora som små att arbeta effektivt och säkert i ett intuitivt och enkelt arbetsflöde. För mer information: www.hoylu.com Kortnamn: Hoylu Marknadsplats: Nasdaq First North Growth Market Certified Adviser: Mangold Fondkommission AB + 46 (0) 8 50 301 550, ca@mangold.se Publicering Denna information är sådan information som Hoylu AB (publ) är skyldig att offentliggöra enli

Hoylu AB: Publishes its Annual Report for 20192.6.2020 23:30:00 CESTPress release

Hoylu AB (publ) announced today that the Annual Report for 2019 is available at Hoylu’s web site: https://www.hoylu.com/investor-relations/financial-reports/ For more information, please contact: Stein Revelsby, CEO at Hoylu +1 213 440 2499 Email: sr@hoylu.com Karl Wiersholm, CFO at Hoylu +1 425 829 2316 Email: kw@hoylu.com About Hoylu Hoylu’s mission is to make remote work and information sharing easy. Through our customizable Connected Workspaces™ we deliver software solutions for companies, organizations and individuals across virtually all industries that enable all teams, big and small to work efficiently and securely in an intuitive and easy workflow. For more information: www.hoylu.com. Ticker symbol: Hoylu Marketplace: Nasdaq First North Growth Market Certified Adviser: Mangold Fondkommission AB +46 (0) 8 50 301 550, ca@mangold.se Publication This information is information that Hoylu AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was s

Novartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis2.6.2020 22:05:00 CESTPress release

Basel, June 2, 2020 — Novartis today announced that it has received notice from the US Food and Drug Administration (FDA) that the agency has extended its review of the Supplemental Biologics License Application (sBLA) for ofatumumab (OMB 157), a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis. Regulatory action is now expected in September 2020. “Novartis will continue to work with the FDA to complete the review as soon as possible,” said Marie-France Tschudin, President, Novartis Pharmaceuticals. “We are well prepared and ready to launch ofatumumab upon approval. We are committed to the MS community and look forward to bringing this important advancement to patients with MS.” Additional regulatory filings are currently underway and regulatory approval for ofatumumab in Europe is expected by Q2 2021. About ofatumumab Ofatumumab (OMB 157) is a fully human anti-CD20 monoclonal antibody (mAb) in development for RMS that is self-adminstered by a o

TIGO is recognized once again as a leading Great Place to Work in Latin America2.6.2020 21:16:48 CESTPress release

TIGO is recognized once again as a leading Great Place to Work in Latin America Luxembourg, June 2nd, 2020 - Millicom’s TIGO operations were ranked among the Top 25 Best Multinational Workplaces in Latin America, across all industries, obtaining the 13th place in the 2020 Great Place to Work® (GPTW) ranking. With more than 20,000 employees in the region, this marks TIGO’s third year ranking as a Great Place to Work. “In today’s world, where uncertainty reigns, our purpose to build digital highways that connect people, improve lives, and develop communities, has never been more important. Our TIGO people make our critical work possible every day and are a vital part of the communities they serve. Through their passion they very much represent what makes TIGO a special place to work, and this recognition continues to validate the extraordinary work we can do as a team,” said Mauricio Ramos, CEO of Millicom. “I am extremely proud and thankful to everyone in our team who continue to demons

INDKALDELSE til ordinær generalforsamling i FLSmidth & Co. A/S2.6.2020 14:46:17 CESTpressemeddelelse

Company Announcement No. 10-2020 Bestyrelsen indkalder herved til ordinær generalforsamling fredag den 26. juni 2020 kl. 16.00 på selskabets adresse, Vigerslev Allé 77, 2500 Valby. Af hensyn til alles sikkerhed og for at mindske risikoen for smittespredning af COVID-19 henstiller vi til, at vores aktionærer ikke møder op fysisk på generalforsamlingen, men brevstemmer eller giver fuldmagt og følger generalforsamlingen via livestreaming på hjemmesiden. Ledelsen vil også være meget begrænset repræsenteret for at mindske smitterisikoen. Dagsorden: Bestyrelsens beretning om selskabets virksomhed i 2019Forelæggelse og godkendelse af årsrapport for 2019Godkendelse af honorarer til bestyrelsen: a. Endelig godkendelse af honorarer for 2019 Bestyrelsen foreslår uændret godkendelse af honorarerne for 2019, som blev forhåndsgodkendt af generalforsamlingen i 2019. Honorarerne er baseret på et grundhonorar på DKK 450.000 (”Grundhonoraret”) med dobbelt honorar til næstformanden og tredobbelt honorar

NOTICE TO CONVENE the Annual General Meeting of FLSmidth & Co. A/S2.6.2020 14:46:17 CESTPress release

Company Announcement No. 10-2020 The Board of Directors hereby convenes the Annual General Meeting to be held on Friday 26 June 2020 at 4 pm (CET) at the offices of the company, Vigerslev Allé 77, DK-2500 Valby. To protect everyone’s safety and reduce the risk of COVID-19 spreading, we recommend that shareholders refrain from attending the general meeting in person and instead cast their votes by postal vote or proxy and attend the live webcast of the general meeting via the web site. The number of representatives from the management will be reduced to reduce the risk of infection. Agenda: The Board of Directors' report on the company’s activities in 2019.Presentation and approval of the 2019 Annual Report.Approval of the Board of Directors’ fees: a. Final approval of fees for 2019. The Board of Directors proposes unchanged approval of the fees for 2019 that were pre-approved by the general meeting in 2019. The fees are based on a base fee of DKK 450,000 (the “Base Fee”) with twice tha